Abstract
To prevent cardiovascular disease (CVD), which is one of the ultimate goals in the management of patients with diabetes, it is important to control not only hyperglycemia, but also modifiable CVD risk factors such as hypertension and dyslipidemia. In addition, antiplatelet agents should be used under appropriate conditions. It is necessary to evaluate whether the patient has CVD, the degree of other complications, the presence of comorbidities or other CVD risk factors, and the duration of diabetes. In this article, I will review the revised and key points of the 8th edition of the Korean Diabetes Association clinical practice guidelines for management of hypertension and dyslipidemia and the use of antiplatelet agents in patients with diabetes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
